NCT07047066尚未招募2 期
A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 30
- 主要终点
- OS
研究概览
简要总结
A Phase II clinical study is planned to evaluate the efficacy and safety of fluzoparib combined with temozolomide in newly diagnosed glioblastoma patients after completing standard concurrent chemoradiotherapy (CCRT), explore the effectiveness and safety of this regimen, and find a better treatment option for glioblastoma patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.Signed informed consent form (ICF);
- •Age ≥18 years old, <70 years old;
- •Based on postoperative MRI, the total resection range is ≥80% compared with preoperative MRI (resection for the purpose of biopsy is not eligible);
- •Patients newly diagnosed with primary glioblastoma by imaging or pathology, completed concurrent chemoradiotherapy (CCRT), and planned to receive adjuvant TMZ treatment;
- •Appropriate hematological treatment and end-organ function within 14 days before randomization, defined by the following laboratory results:
- •Absolute neutrophil count (ANC) ≥1.5×109/L;
- •Platelet count ≥100×109/L;
- •Hemoglobin ≥90 g/L;
- •Total bilirubin ≤1.5 ×ULN;
- •AST and ALT ≤3 × ULN;
- •Alkaline phosphatase ≤2.5 × ULN;
- •Serum albumin ≥25 g/L;
- •Serum creatinine ≤133 μmol/L;
- •PT and aPTT ≤ 1.5 × ULN;
- •Karnofsky score ≥ 60;
- •Expected survival > 12 weeks;
- •Women of childbearing age*: must use highly effective contraceptive methods (resulting in a contraceptive failure rate of <1% per year) from the date of informed consent until at least 3 months after the last dose of the study drug fluzoparib/TMZ (whichever occurs later).
- •Men: agree to use contraceptive measures, defined as follows: For female partners of childbearing potential or pregnant female partners, men must use highly effective contraceptive methods from the date of informed consent until at least 3 months after the last dose of the study drug fluzoparib/TMZ (whichever occurs later).
- •*Women are postmenopausal women who have not reached postmenopausal status (continuous amenorrhea for ≥ 12 months without a confirmed cause other than menopause) and have not undergone surgical sterilization (removal of the ovaries and/or uterus).
排除标准
- •During the concurrent chemoradiotherapy phase, the total radiotherapy dose is >60Gy;
- •Multifocal glioma (≥3 lesions);
- •Patients with primary infratentorial glioblastoma;
- •Patients with leptomeningeal disease;
- •Patients with stable or no dose reduction of corticosteroids within 14 days of randomization;
- •Pregnancy, lactation or breastfeeding (need to breastfeed or breastfeed during the study);
- •Women of childbearing age (including women who have undergone tubal ligation) must undergo a blood pregnancy test
- •Major cardiovascular disease, including New York Heart Association heart disease (grade 2 or higher), myocardial infarction within 3 months before randomization, unstable arrhythmia requiring treatment within the first 3 months, and/or newly diagnosed unstable angina;
- •Known clinically significant liver disease, including active viral, alcoholic or other hepatitis, cirrhosis, and hereditary liver disease;
- •Poorly controlled type 2 diabetes, defined as glycated hemoglobin ≥8% or fasting blood glucose ≥8.8 during the screening period mmol/L;
- •Major surgery (requiring general anesthesia) is expected during the study;
- •Any severe or uncontrollable systemic disease, including uncontrollable hypertension (defined as blood pressure still higher than 150/90 mmHg after effective antihypertensive treatment) and active bleeding disorders;
- •Any anticancer treatment after CCRT, whether experimental or approved, including chemotherapy, immunotherapy, gene therapy, cancer vaccine, cell therapy, cytokine/hormone therapy, and/or radiotherapy;
- •Persistent toxicity related to previous treatment (according to NCI CTCAE v5.0 toxicity level as > 1); according to the investigator's judgment, alopecia, sensory neuropathy ≤ 2, or other safety risk level ≤ 2 are eligible for inclusion;
- •Malignant tumors other than the study disease within 5 years before randomization, except for patients without risk of death or metastasis (adequately treated cervical carcinoma in situ, basal or squamous cell skin cancer, localized prostate cancer or ductal carcinoma in situ);
- •During the screening period, patients have active viral infections that require systemic treatment:
- •HIV antibody positive;
- •Active hepatitis B: defined as HBsAg positive or HBcAb positive, and HBV DNA test result > 2000 IU/mL;
- •Active hepatitis C: defined as HCV antibody positive and PCR test HCV RNA positive. However, subjects with positive serum anti-HCV and negative HCV RNA can also be included;
- •Syphilis infection (positive Treponema pallidum specific antibody);
- •Patients who the investigator believes are not suitable for participation in the trial or will violate the protocol
研究组 & 干预措施
Fluzoparib combined with Temozolomide
Experimental
干预措施: Fluzoparib with Temozolomide (Drug)
结局指标
主要结局
OS
时间窗: Patients were assessed up to 36 months from enrollment to first death (whichever occurred first)
Defined as the time from the date of randomization to death from any cause.
次要结局
- PFS(From enrollment to the first appearance of disease progression or date death from any cause,whichever came first,assessed up to 36 mounths)
- ORR(From enrollment to initial efficacy evaluation ,assessed up to 6 months)
研究者
相似试验
终止
2 期
Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell LymphomaMantle Cell LymphomaNCT00183989University of Southern California30
终止
2 期
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.Acute Myeloid Leukemia, AdultAML, AdultAMLNCT04425655University of California, San Diego2
尚未招募
2 期
The Efficacy and Safety of The Fuzuloparib Combination With BevacizumabRecurrent Ovarian CancerNCT05819060Fudan University44
已完成
1 期
A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung CancerSmall Cell Lung CancerNCT04400188Jiangsu HengRui Medicine Co., Ltd.25
已完成
2 期
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 YearsChronic Lymphocytic LeukemiaNCT00254410M.D. Anderson Cancer Center30